Clinical Trials Logo

Recurrent Neuroblastoma clinical trials

View clinical trials related to Recurrent Neuroblastoma.

Filter by:

NCT ID: NCT00053326 Completed - Clinical trials for Recurrent Neuroblastoma

Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

Start date: May 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well fenretinide works in treating children with recurrent or resistant neuroblastoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00030667 Completed - Clinical trials for Gastrointestinal Stromal Tumor

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Start date: May 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

NCT ID: NCT00028522 Completed - Clinical trials for Recurrent Neuroblastoma

R(+)XK469 in Treating Patients With Advanced Neuroblastoma

Start date: December 2001
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of R(+)XK469 in treating patients with advanced neuroblastoma. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.

NCT ID: NCT00026312 Active, not recruiting - Clinical trials for Recurrent Neuroblastoma

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Start date: October 18, 2001
Phase: Phase 3
Study type: Interventional

This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.

NCT ID: NCT00012181 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Start date: April 2001
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid tumors or lymphoma.

NCT ID: NCT00005576 Completed - Clinical trials for Recurrent Neuroblastoma

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Start date: January 2001
Phase: Phase 1
Study type: Interventional

Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining monoclonal antibody therapy with sargramostim or interleukin-2 may kill more tumor cells. Phase I trial to study the effectiveness of monoclonal antibody therapy given with sargramostim and interleukin-2 in treating children with neuroblastoma who have just completed bone marrow or peripheral stem cell transplantation

NCT ID: NCT00004078 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Irinotecan in Treating Children With Refractory Solid Tumors

Start date: October 1999
Phase: Phase 2
Study type: Interventional

This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.